XDx Announces Positive Results from European CARGO II Study of AlloMap(R ... MarketWatch (press release) AlloMap is XDx's FDA-cleared and CE-marked, easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient's risk of acute cellular rejection without requiring the use of endomyocardial biopsy. |
